Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
wikitox:sympathomimetic_toxicity [2024/07/24 01:35] – kharris | wikitox:sympathomimetic_toxicity [2025/07/17 20:28] (current) – [Sympathomimetic Toxicity] kharris | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== | + | ====== |
- | < | + | |
- | + | ||
- | ---- | + | |
Sympathomimetic toxicity is commonly seen following recreation drug use, but may also result from excessive use or overdose of a number of pharmaceuticals. | Sympathomimetic toxicity is commonly seen following recreation drug use, but may also result from excessive use or overdose of a number of pharmaceuticals. | ||
Line 8: | Line 5: | ||
It presents largely as one of adrenergic excess, with the CNS and CVS most notably effected. Treatment is largely supportive along with the provision of adequate sedation. | It presents largely as one of adrenergic excess, with the CNS and CVS most notably effected. Treatment is largely supportive along with the provision of adequate sedation. | ||
- | ---- | ||
===== Sympathomimetic Agents ===== | ===== Sympathomimetic Agents ===== | ||
- | Agents causing | + | Agents causing |
Illicit substances: | Illicit substances: | ||
Line 19: | Line 15: | ||
* Cocaine | * Cocaine | ||
* Beta-adrenergic receptor agonists e.g. clenbuterol | * Beta-adrenergic receptor agonists e.g. clenbuterol | ||
- | * Novel psychoactives - including novel stimulants, novel hallucinogenic agents, and synthetic cannabinoid-receptor | + | * Novel psychoactives - including novel stimulants, novel hallucinogenic agents, and synthetic cannabinoid-receptor |
- | Pharmaceuticals | + | Pharmaceuticals: |
- | * Beta-adrenergic receptor | + | * Beta-adrenergic receptor |
* Catecholamines e.g. adrenaline, noradrenaline, | * Catecholamines e.g. adrenaline, noradrenaline, | ||
* Psychostimulants e.g. modafinil | * Psychostimulants e.g. modafinil | ||
* Indirect sympathomimetics e.g. dexamfetamine, | * Indirect sympathomimetics e.g. dexamfetamine, | ||
* Monoamine inhibitors e.g. phenelzine | * Monoamine inhibitors e.g. phenelzine | ||
- | * Serotonin and Noradrenaline reuptake inhibitors (SNRIs) e.g. venlafaine, atomoxetine | + | * Serotonin and Noradrenaline reuptake inhibitors (SNRIs) e.g. venlafaxine, atomoxetine |
- | * Xanthines e.g. caffeine, | + | * Xanthines e.g. caffeine, |
+ | <font inherit/ | ||
---- | ---- | ||
- | ===== Mechanism of toxic effects | + | ===== Mechanism of Toxic Effects |
- | There is some variability depending on the causative agent but in genreal | + | There is some variability depending on the causative agent but in general |
- | The increase in noradrenaline mostly leads to the cardiovascular signs, dopamine to the behavioural and psychotic symptoms and serotnin | + | The increase in noradrenaline mostly leads to the cardiovascular signs, dopamine to the behavioural and psychotic symptoms and serotonin |
- | ---- | ||
===== Clinical Presentation ===== | ===== Clinical Presentation ===== | ||
- | The sympathomimetic toxidrome can vary both in severity and the range of symptoms | + | The sympathomimetic toxidrome can vary both in severity and the range of symptoms |
* Central Nervous system | * Central Nervous system | ||
* Excitation - agitation, anxiety, delirium | * Excitation - agitation, anxiety, delirium | ||
- | * Acute behavioural | + | * Acute behavioural |
- | * Haemorrhagic or thrombotic | + | * Haemorrhagic or thrombotic |
* Cardiovascular effects | * Cardiovascular effects | ||
* Tachycardia, | * Tachycardia, | ||
Line 59: | Line 55: | ||
* Mydriasis | * Mydriasis | ||
* Neuromuscular effects | * Neuromuscular effects | ||
- | * Excitation - tremor, | + | * Excitation - tremor, |
* Metabolic effects | * Metabolic effects | ||
* Hypokalaemia | * Hypokalaemia | ||
Line 70: | Line 66: | ||
===== Management ===== | ===== Management ===== | ||
- | The main goal of treatment is to control agitation and aggression and identify and treat any life threats | + | The main goal of treatment is to control agitation and aggression and identify and treat any complications |
- | In most cases the paramount and often only treatment | + | In most cases the paramount and often only treatment |
- | When treating non-agitation | + | When treating non-agitation |
- | // | + | **// |
In those with mild symptoms, oral sedation may be adequate to control behaviour. Use: | In those with mild symptoms, oral sedation may be adequate to control behaviour. Use: | ||
* **Diazepam 5-20mg (Child 0.2mg/kg up to 10mg)**. Repeat after 20 mins if required. | * **Diazepam 5-20mg (Child 0.2mg/kg up to 10mg)**. Repeat after 20 mins if required. | ||
- | * **Olanzapine 5-10mg**, orally. Repeat at 20 mins if requried. | + | * **Olanzapine 5-10mg**, orally. Repeat at 20 mins if required. |
In those with severe agitation or who fail to respond to oral sedation, parenteral sedation is often required: Options include: | In those with severe agitation or who fail to respond to oral sedation, parenteral sedation is often required: Options include: | ||
Line 88: | Line 84: | ||
Droperidol appears particularly effective in treating those affected by recreational stimulants. These agents tend to cause very high dopamine levels which droperidol likely treats due to it high dopamine receptor blocking effects. | Droperidol appears particularly effective in treating those affected by recreational stimulants. These agents tend to cause very high dopamine levels which droperidol likely treats due to it high dopamine receptor blocking effects. | ||
- | // | + | **// |
- | It is common for patients with sympathomimetic toxicity to have a raised temperature. Severe hyperthermia | + | It is common for patients with sympathomimetic toxicity to have a raised temperature. Severe hyperthermia |
- | // | + | **// |
If hypertension is severe and does not respond to sedation, then use: | If hypertension is severe and does not respond to sedation, then use: | ||
* **glyceryl trinitrate 10 mcg/ | * **glyceryl trinitrate 10 mcg/ | ||
- | If blood pressure is not controlled despite this then discuss with a clinical toxicologist for further advice (e.g. beta-blockade). | + | If blood pressure is not controlled despite this, then discuss with a clinical toxicologist for further advice (e.g. beta-blockade). |
//Other complications// | //Other complications// | ||
Line 106: | Line 102: | ||
* Coronary artery spasm or dissection are more common in this group which should be a consideration when discussing with cardiology as primary angiogram is likely to be preferred in favour of thrombolysis in this group. | * Coronary artery spasm or dissection are more common in this group which should be a consideration when discussing with cardiology as primary angiogram is likely to be preferred in favour of thrombolysis in this group. | ||
* Specific advice regarding drug induced rhabdomyolysis can be found [[: | * Specific advice regarding drug induced rhabdomyolysis can be found [[: | ||
+ | |||
+ | ===== Educational Resources ===== | ||
+ | |||
+ | [[https:// | ||